MetaBiom
Microbiome & Chronic Diseases

Evidence Based Medicine
Sign in

Migraine {40000136}

Record Keys


Definition:
Migraine
Class:[  ]

Details


Other Terms:[  ]
Initialisation date:
2020-09-06

Links


Meta Information


ICD:[  ]
Category:
Neurology
MedDra ID:
10027599
MedDra Level:
pt

Notes


[  ]

Shared Notes


  • [1.2
    - These results suggest that bacteria in the mouth may therefore contribute to efficient breakdown of nitrate contained in foods and food preservatives, which are finally converted into nitric oxide in the bloodstream, causing vessels in the brain and scalp to dilate.
    Pseudomonas have the potential to reduce nitrate.
    - Streptococcus and Pseudomonas, both of which have species with the potential to reduce nitrate.
  • [1.3
    - H. pyloriis exposed to fairly high concentrations of NO in gastric juice, which has low oxygen tension.
    - NO directly inhibits the respiration of E. coli whereas it rapidly reacts with endogenously generated superoxide radicals in H. pylori. The resulting peroxynitrite inactivates the respiration of H. pylori.
  • [1.4
    - Subjects affected by primary headache have a H. pylori infection prevalence of 40%.
    - It also found a higher prevalence of migraine without aura in infected patients.
    - Higher IgM antibody titers against H. pylori in PWM compared to controls.
    - A positive correlation between IgG antibody titers and severity of migraine.
    - The serum levels of CGRP, which has been suggested as a biomarker for chronic migraine are also higher in those with H. pylori-associated duodenal ulcers compared with healthy controls.


[Coverage other Diseases (Overlap > 0.25)]

DiseaseOverlapCommon increased OrganismCommon decreased Organism
Migraine 1.0000 16 (100%) : Blautia hydrogenotrophica | Campylobacter jejuni | Clostridium asparagiform | Clostridium boltae | Clostridium citroniae | Clostridium clostridioforme | Clostridium hathewayi | Clostridium ramosum | Clostridium spiroforme | Clostridium symbiosum | Eggerthella lenta | Flavonifractor plautii | Lachnospiraceae | Pseudomonas | Ruminococcus gnavus | Streptococcus 3 (100%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii | Methanobrevibacter smithii
Autism 0.7083 12 (75%) : Clostridium asparagiform | Clostridium boltae | Clostridium clostridioforme | Clostridium hathewayi | Clostridium ramosum | Clostridium symbiosum | Eggerthella lenta | Flavonifractor plautii | Lachnospiraceae | Pseudomonas | Ruminococcus gnavus | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Type 2 diabetes 0.6458 10 (63%) : Clostridium boltae | Clostridium clostridioforme | Clostridium hathewayi | Clostridium ramosum | Clostridium symbiosum | Eggerthella lenta | Lachnospiraceae | Pseudomonas | Ruminococcus gnavus | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Crohn's disease 0.5521 7 (44%) : Clostridium boltae | Clostridium ramosum | Flavonifractor plautii | Lachnospiraceae | Pseudomonas | Ruminococcus gnavus | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Cystic fibrosis 0.4896 5 (31%) : Clostridium clostridioforme | Lachnospiraceae | Pseudomonas | Ruminococcus gnavus | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Lung cancer 0.4271 3 (19%) : Lachnospiraceae | Ruminococcus gnavus | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Non-alcoholic fatty liver disease 0.3958 2 (13%) : Lachnospiraceae | Streptococcus 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Obesity 0.3958 2 (13%) : Clostridium symbiosum | Pseudomonas 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Inflamatory bowel disease 0.3958 2 (13%) : Clostridium hathewayi | Ruminococcus gnavus 2 (67%) : Faecalibacterium prausnitzii | Methanobrevibacter smithii
Cavernous angioma 0.3333 0 (0%) 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Inactive Crohn's Disease 0.3333 0 (0%) 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Keratitis 0.3333 0 (0%) 2 (67%) : Bifidobacterium adolescentis | Faecalibacterium prausnitzii
Ulcerative Colitis 0.2917 4 (25%) : Clostridium ramosum | Flavonifractor plautii | Ruminococcus gnavus | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Colorectal cancer 0.2917 4 (25%) : Clostridium ramosum | Clostridium symbiosum | Pseudomonas | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Parkinson's Disease 0.2917 4 (25%) : Clostridium spiroforme | Eggerthella lenta | Lachnospiraceae | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Atherosclerosis 0.2604 3 (19%) : Eggerthella lenta | Ruminococcus gnavus | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Systemic lupus erythematosus 0.2604 3 (19%) : Lachnospiraceae | Pseudomonas | Ruminococcus gnavus 1 (33%) : Faecalibacterium prausnitzii
Chronic kidney disease 0.2604 3 (19%) : Pseudomonas | Ruminococcus gnavus | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Cirrhosis 0.2604 3 (19%) : Pseudomonas | Ruminococcus gnavus | Streptococcus 1 (33%) : Faecalibacterium prausnitzii
Covid-19 0.2604 3 (19%) : Clostridium hathewayi | Clostridium ramosum | Streptococcus 1 (33%) : Faecalibacterium prausnitzii

[Coverage Factors (Overlap > 0.10)]

FactorOverlapCommon increased OrganismCommon decreased Organism
Chemotherapy treatment 0.1667 0 (0%) 1 (33%) : Faecalibacterium prausnitzii
Consumption of Iron sulfat 0.1667 0 (0%) 1 (33%) : Faecalibacterium prausnitzii

Common References